201June July 12, China Food and Drug Administration approved the application for import registration of GlaxoSmithKline preventive biological products and human papillomavirus adsorption vaccine. This product is a bivalent vaccine prepared by expressing recombinant HPV 16 and 18 virus-like particles in baculovirus expression system, and adding MPL and aluminum hydroxide adjuvant after purification. This vaccine is the first application for marketing in China, and the research data show that the safety and effectiveness of its application in domestic target population are consistent with those of foreign countries. The approval of this vaccine provides a new and effective means for the prevention of cervical cancer in China.